A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

A. Belch, W. Shelley, D. Bergsagel, K. Wilson, Paul Klimo, D. White, A. Willan

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

In order to assess the role of maintenance melphalan and prednisone (MP) in responding multiple myeloma patients, 185 eligible patients who responded to initial MP with stabilization for at least 4 months were randomized to either stop treatment and resume therapy at relapse or to continue MP until relapse. Time to first relapse was significantly shorter in the no maintenance group (P=0.0011), however 57% of the no maintenance patients had a second response when MP was restarted and others had minor improvement. The time to final progression on MP, which reflects the duration of disease control by MP, was therefore longer for the no maintenance group (median=39 months) compared to the maintenance group (median=31 months) although the observed difference was not statistically significant (P=0.086). Median survival from start of MP in the maintenance group (46 months) was also not significantly different than the no maintenance group (51 months) (P=0.587). Multifactor analysis of the randomized patients demonstrated shorter total remission duration and shorter survival in patients who had an initially rapid response to therapy or a lesser reduction in serum M-protein concentration.

Original languageEnglish (US)
Pages (from-to)94-99
Number of pages6
JournalBritish Journal of Cancer
Volume57
Issue number1
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Melphalan
Prednisone
Multiple Myeloma
Maintenance
Recurrence
Survival
Blood Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. / Belch, A.; Shelley, W.; Bergsagel, D.; Wilson, K.; Klimo, Paul; White, D.; Willan, A.

In: British Journal of Cancer, Vol. 57, No. 1, 01.01.1988, p. 94-99.

Research output: Contribution to journalArticle

Belch, A. ; Shelley, W. ; Bergsagel, D. ; Wilson, K. ; Klimo, Paul ; White, D. ; Willan, A. / A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. In: British Journal of Cancer. 1988 ; Vol. 57, No. 1. pp. 94-99.
@article{18544e4817094dc498799e0a81c09a65,
title = "A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients",
abstract = "In order to assess the role of maintenance melphalan and prednisone (MP) in responding multiple myeloma patients, 185 eligible patients who responded to initial MP with stabilization for at least 4 months were randomized to either stop treatment and resume therapy at relapse or to continue MP until relapse. Time to first relapse was significantly shorter in the no maintenance group (P=0.0011), however 57{\%} of the no maintenance patients had a second response when MP was restarted and others had minor improvement. The time to final progression on MP, which reflects the duration of disease control by MP, was therefore longer for the no maintenance group (median=39 months) compared to the maintenance group (median=31 months) although the observed difference was not statistically significant (P=0.086). Median survival from start of MP in the maintenance group (46 months) was also not significantly different than the no maintenance group (51 months) (P=0.587). Multifactor analysis of the randomized patients demonstrated shorter total remission duration and shorter survival in patients who had an initially rapid response to therapy or a lesser reduction in serum M-protein concentration.",
author = "A. Belch and W. Shelley and D. Bergsagel and K. Wilson and Paul Klimo and D. White and A. Willan",
year = "1988",
month = "1",
day = "1",
doi = "10.1038/bjc.1988.17",
language = "English (US)",
volume = "57",
pages = "94--99",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

AU - Belch, A.

AU - Shelley, W.

AU - Bergsagel, D.

AU - Wilson, K.

AU - Klimo, Paul

AU - White, D.

AU - Willan, A.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - In order to assess the role of maintenance melphalan and prednisone (MP) in responding multiple myeloma patients, 185 eligible patients who responded to initial MP with stabilization for at least 4 months were randomized to either stop treatment and resume therapy at relapse or to continue MP until relapse. Time to first relapse was significantly shorter in the no maintenance group (P=0.0011), however 57% of the no maintenance patients had a second response when MP was restarted and others had minor improvement. The time to final progression on MP, which reflects the duration of disease control by MP, was therefore longer for the no maintenance group (median=39 months) compared to the maintenance group (median=31 months) although the observed difference was not statistically significant (P=0.086). Median survival from start of MP in the maintenance group (46 months) was also not significantly different than the no maintenance group (51 months) (P=0.587). Multifactor analysis of the randomized patients demonstrated shorter total remission duration and shorter survival in patients who had an initially rapid response to therapy or a lesser reduction in serum M-protein concentration.

AB - In order to assess the role of maintenance melphalan and prednisone (MP) in responding multiple myeloma patients, 185 eligible patients who responded to initial MP with stabilization for at least 4 months were randomized to either stop treatment and resume therapy at relapse or to continue MP until relapse. Time to first relapse was significantly shorter in the no maintenance group (P=0.0011), however 57% of the no maintenance patients had a second response when MP was restarted and others had minor improvement. The time to final progression on MP, which reflects the duration of disease control by MP, was therefore longer for the no maintenance group (median=39 months) compared to the maintenance group (median=31 months) although the observed difference was not statistically significant (P=0.086). Median survival from start of MP in the maintenance group (46 months) was also not significantly different than the no maintenance group (51 months) (P=0.587). Multifactor analysis of the randomized patients demonstrated shorter total remission duration and shorter survival in patients who had an initially rapid response to therapy or a lesser reduction in serum M-protein concentration.

UR - http://www.scopus.com/inward/record.url?scp=0023870374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023870374&partnerID=8YFLogxK

U2 - 10.1038/bjc.1988.17

DO - 10.1038/bjc.1988.17

M3 - Article

VL - 57

SP - 94

EP - 99

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -